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The relationship between vitamin D metabolic enzymes (CYP27A1, CYP27B1, and 
CYP24A1) and vitamin D receptor (VDR) in non-melanoma skin cancer (NMSC) 
development and progression is not entirely clear. However, several clinical studies and in 
vitro reports indicate a connection between vitamin D metabolic key players and NMSCs 
by demonstrating inhibitory effects on tumor cells and positive effects of higher circulatory 
25-hydroxyvitamin D in skin cancer prevention [1]. Vitamin D synthesis is mediated via 
mitochondrial cytochrome P450 family hydroxylase enzymatic reactions: anabolic and 
catabolic hydroxylases (CYP27A1, CYP27B1, and CYP24A1). The importance of vitamin 
D mitochondrial enzymes in some cancers have been reported, however their role in NMSC 
requires further evaluation. CYP24A1 protein expression in lung adenocarcinoma patients 
was reported up to 50 folds greater compared to healthy lung and significantly higher in 
poorly differentiated cancers types. The survival was proportional to the level of CYP24A1 
expression (42% survival with high CYP24A1 expression versus 81% survival with low 
level CYP24A1). The overexpression of CYP24A1 in lung cancer was concluded to have 
an association with poor survival in lung adenocarcinoma patients. Since endogenous 
vitamin D degradation is tightly controlled by CYP24A1, the abrogation of vitamin D 
antiproliferative effects in lung cancers may be due to CYP24A1 overexpression [2]. It is 
clear that low circulatory vitamin D levels are linked to decreased VDR activity in 
endometrial and breast cancer, and deletion of VDR results in decreased tumor suppressor 
genes (H19, HOTTIP, Nespas, Kcnq1ot1, lincRNA-p21, Foxn2-as, Gtl2-as, and H19-as) and 
increased oncogenes (mHOTAIR, Malat1, and SRA). In fact, VDR suppresses oncogenes, 
induces tumor suppressor genes, inhibits cell proliferation and migration of malignant cells, 
and prevents metastasis and angiogenesis in cancer [3]. Interestingly, VDR single nucleotide 
polymorphisms have been linked to actinic keratosis (AK) development and poor survival of 
melanoma patients [4]. These reports indicated that polymorphisms in VDR resulted in less 
transcriptionally active VDR, with less efficient interactions with transcriptional factors and 
decreased growth inhibition by vitamin D [5]. It is suggested that VDR and vitamin D 
metabolic enzymes interact with tumor regulatory proteins in malignant cells, influencing 
tumor formation, growth and preventing angiogenic spread [6]. Hence, tumor promotion 
and progression is connected to VDR and its metabolic enzymes. Vitamin D hydroxylases 
may play an important role in tumorigenesis. Their functions extend beyond vitamin D 
synthesis and degradation. Reduced enzymatic activity of CYP27B1 is noted in aggressive 
types of melanomas [7]. CYP27A1 modulates VDR activation and plays a pivotal role in 
carcinogenesis. The preventative effects of high endogenous vitamin D levels in the 
development of neoplastic growth and its aggressiveness have been demonstrated. 
Metastatic types of NMSC are often associated with squamous cell carcinoma (SCC) lesions. 
However the most common type of NMSC is basal cell carcinoma (BCC) and AK known as 
a common precursor of SCC, which has the potential for metastatic spread [8]. BCC and SCC 
have important morphological differences and different metastatic potential. Whilst 
metastatic BCC is a less common condition, both BCC and SCC are malignant. Therefore, it 
is crucial to establish the status of intratumoral vitamin D enzymes and receptor.    
 Herein, the intratumoral expression of mitochondrial vitamin D enzymes and VDR in 
BCC, SCC, SCC in situ (SCCIS), AK and normal skin were determined by standard 
immunohistochemistry (IHC) tissue staining using biotinylated universal antibody 
streptavidin–biotin (LSAB+) System–HRP (K4063) and diaminobenzidine (Dako Botany, 
Australia). The primary unconjugated polyclonal antibodies (Santa Cruz Biotechnology, 
Santa Cruz, USA) were used at the optimized dilutions (1:1000): goat anti-human 
CYP27A1, rabbit anti-human CYP27B1, rabbit anti-human CYP24A1, and rabbit 
anti-human VDR. The secondary antibodies (Dako) were also used at their optimized 
dilutions (1:500): anti-mouse HRP, polyclonal rabbit anti-goat Ig, and polyclonal goat 
anti-rabbit Ig. All antibodies as supplied by the respective companies were characterized 
and validated for specificity by western blotting [9]. Tissue sections were received from the 
Department of Dermatology, St Vincent’s Hospital (Melbourne, Australia) or purchased 
from Resolving Images Pty Ltd (Melbourne, Australia). In total, 20 BCCs, 15 AKs, 12 
SCCISs, 8 SCCs and 5 normal skin tissues were stained from patients aged 41–93 years 
following informed consent and human ethics was obtained from the Department of 
Dermatology, St Vincent’s Hospital and Victoria University, Australia. Detections of 
vitamin D metabolic enzymes (CYP27A, CYP27B1 and CYP24A1) and its receptors (VDR) 
in human NSK, AK, BCC, SCC and SCCIS are shown in Figs. 1 and 2. A summary of tissues 
stained with respective antibodies and expression levels and number of tissues positive are 
shown in Table 1. VDR showed uniform moderate to high expression in most tissues 
particularly in epidermal keratinocytes and to a lesser degree in keratinocytes of basal layers 
in AK, SCC and SCCIS. The expression of VDR in BCC is present in keratinocytes of all 
epidermal layers. In addition, VDR was shown to have a statistically significant association 
with CYP24A1 in all tumors, but not with NSK (P<0.001). CYP27A1 detection was very 
prominent in NSK, AK and SCCIS, with lower expression in some SCC and BCC. 
CYP27A1 expression was strongly associated (P<0.05) with CYP24A1 expression in BCC 
and SCCIS and almost reached significant association with CYP24A1 expression in SCC 
(P=0.052), and no association in NSK (P>0.05). CYP27B1 was expressed in NSK and most 
SCCIS with lower expression in most precancerous (AK) tissues and cancerous tissues (BCC 
and SCC). Inverse significant association was noted between CYP27B1 and CYP24A1 
expression in all NMSC lesions, but not in NSK. The distribution of CYP24A1 expression 
was very different in all tumors and NSK. In AK, BCC, SCC and SCCIS there was intense 
CYP24A1 expression, whereas in most NSK tissues the expression of CYP24A1 was 
decreased. Specificity of the antibodies used on normal keratinocytes and malignant 
squamous keratinocytes (SCC-4 cells), and the effects of calcidiol and calcitriol on the 
expression of CYP27A1, CYP27B1, CYP24A1, and VDR on these cell lines were confirmed 
and assessed by western blotting (data not shown). The expression and correlation analysis of 
vitamin D metabolic proteins and VDR in tumor sections and normal skin was determined by 
IBM Statistical Package for the Social Sciences (SPSS) software using Multivariable 
Cross-tabulation Chi-Square test. Correlations were considered statistically significant with 
P < 0.05. 
 In summary, vitamin D metabolic enzymes and VDR expression in human NMSC 
were found to have statistically significant correlations amongst CYP27A1, CYP24A1 and 
VDR, but not CYP27B1. We present data that shows CYP27B1 to be diminished in 
NMSC, compared to normal skin, whilst CYP24A1 was elevated in most tumors, but not in 
normal skin. These findings are consistent with previous studies in ovarian carcinomas 
[10], where CYP24A1 overexpression in malignant cells was noted, whilst CYP27B1 
expression was highly reduced.  
 We report crucial differences in the expression of CYP27B1 and CYP24A1 in normal 
and neoplastic tissues. These findings contribute to a better understanding of vitamin D 
metabolism in cutaneous carcinogenesis and could be used as an aid in the management of 
NMSC, particularly for further prognosis of disease recurrence. 
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Figure Legends 
 
Figure 1. Immunoperoxidase staining of skin tissues (NSK, AK, BCC, BCC, SCC, 
SCCIS) for the expressions of VDR, CYP27A1, CYP27B1 and CYP24A1  Disruptions 
of the basal membrane by neoplastic keratinocytes are indicated with ‘diamond-ended’ 
arrows. Immune cell infiltration is shown with ‘circled-ended’ arrows. The positively stained 
neoplastic, premalignant and normal keratinocytes are shown with solid black arrows and are 
indicative of the tissue staining intensity. Poorly differentiated keratinocytes are shown with 
black dashed arrows, where applicable. Scale bar: 20 µm. E, epidermal layer; D, dermal 
layer.  
 
Figure 2. High magnification immunoperoxidase staining of skin tissues (AK, BCC, 
SCC) for the expressions of CYP27B1 and CYP24A1  At high magnification (x 400) in 
hyperproliferative and poorly differentiated keratinocytes minimal expression of CYP27B1 
is noticeable. Elevated CYP24A1 expression is noted in AK and most BCC and SCC tissues. 
Scale bar: 50 µm. 
 
Table 1. The expressions of VDR, CYP27A, CYP27B1 and CYP24A1 in NMSC tissues 
and normal skin 
 


  
 
Table 1. The expression of VDR, CYP27A, CYP27B1 and CYP24A1 in NMSC tissues and 
 normal skin 
Protein Low levels of 
expression 
(0-5%) 
Moderate levels 
of expression 
(5-10%) 
High levels of 
expression  
(> 10%) 
Normal skin 
Vitamin D CYP27A1 (CYP27A1) 0 0 5 
 CYP27B1 (CYP27B1) 1 1 3 
Vitamin D3 24-hydroxylase 
(CYP24A1) 
3 1 1 
VDR 0 0 5 
Actinic keratosis neoplastic lesions 
Vitamin D CYP27A1 (CYP27A1) 0 2 13 
CYP27B1 (CYP27B1) 9 2 4 
Vitamin D3 24-hydroxylase 
(CYP24A1) 
0 0 15 
VDR 1 2 12 
Basal cell carcinoma 
Vitamin D CYP27A1 (CYP27A1) 5 6 10 
CYP27B1 
(CYP27B1) 
12 5 4 
Vitamin D3 24-hydroxylase 
(CYP24A1) 
1 3 17 
VDR 1 2 18 
Squamous cell carcinoma 
Vitamin D CYP27A1 (CYP27A1) 2 4 2 
CYP27B1 (CYP27B1) 4 4 0 
Vitamin D3 24-hydroxylase 
(CYP24A1) 
1 2 5 
VDR 1 4 3 
Squamous cell carcinoma in situ 
Vitamin D CYP27A1 (CYP27A1) 2 2 8 
 CYP27B1 (CYP27B1) 3 9 0 
Vitamin D3 24-hydroxylase 
(CYP24A1) 
1 2 9 
VDR 2 2 8 
 
 
  
Supplementary Table 
The association of CYP24A1 with CYP27A1, CYP27B1 and VDR expression in NMSC; The 
multivariable Cross-tabulation Chi-Square analysis  
 
CYP24A1 CYP27A1 CYP27B1 VDR 
NSK AK BCC SCC SCCIS NSK AK BCC SCC SCCIS NSK AK BCC SCC SCCIS 
Pearson 
Correlatio
n R values 
-0.802 
 
0.708 0.691 0.750 0.875 0.563 -0.183 -0.383 -0.707 -0.93 0.698 -0.808 
. 
0.991 0.832 0.955 
p values 0.096 0.03 0.001 0.052 0.0002 0.324 0.05 0.044 0.048 0.002 0.101 0.001 0.0001 0.001 0.001 
 
